1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Henlius Doses First Patient In China For Ophthalmic Bevacizumab

Follows US FDA Approving Henlius’ Investigational New Drug Application

 
• By Dean Rudge

Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.

Eye
Henlius has also developed bevacizumab for cancer • Source: Shutterstock

Shanghai Henlius Biotech Co. Ltd. has announced that the first patient has been dosed in the company’s Phase I clinical trial in China for its HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration, marking further progress for potentially “one of the first bevacizumab products approved for ophthalmic diseases.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.